Press Releases

Date Title and Summary View
September 5, 2013 Eleven Biotherapeutics to Present at the Stifel Nicolaus 2013 Healthcare Conference View HTML
June 28, 2013 Eleven Biotherapeutics Appoints Industry Veteran Karen L. Tubridy as Chief Development Officer View HTML
June 28, 2013 Eleven Biotherapeutics Announces Positive Topline Data on EBI-005, a Novel Topical IL-1 Inhibitor Protein Therapeutic, in Patients with Dry Eye Disease View HTML
May 28, 2013 Eleven Biotherapeutics Announces Collaboration with ThromboGenics to Develop a Novel Protein Therapeutic for Ophthalmic Disease View HTML
May 8, 2013 Eleven Biotherapeutics Presents Data on EBI-005, a Novel IL-1 Inhibitor Protein Therapeutic for Topical Treatment of Dry Eye Disease View HTML
April 24, 2013 Eleven Biotherapeutics to Present Data on Lead Drug Candidate, EBI-005, at the ARVO 2013 Annual Meeting View HTML
February 19, 2013 Eleven Biotherapeutics Publishes Data on EBI-005, a Novel IL-1 Inhibitor Protein for Topical Treatment of Dry Eye Disease View HTML
December 19, 2012 Eleven Biotherapeutics Initiates Phase 1b Clinical Study of EBI-005, a Novel, Topically Delivered IL-1 Inhibitor Protein for the Treatment of Dry Eye Disease View HTML
May 8, 2012 Eleven Biotherapeutics Secures $20 Million and Expands Series A Financing View HTML
April 24, 2012 Eleven Biotherapeutics to Present at the ARVO 2012 Annual Meeting View HTML